3 completed, 2 recruiting, 1 active not recruiting, 1 available. 3 Phase 2, 3 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow BHV-4157: new trials by email Literature Review of BHV-4157 trials Research Report on BHV-4157
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma Troriluzole - Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Recruiting | Ugonma Chukwueke | 27 | 2025-02-19 | 2025-09-11 |
| Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets Ipilimumab, Nivolumab, Troriluzole - Melanoma, Metastatic Melanoma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 1 | 2021-06-30 | 2024-03-26 |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Temozolomide, Lomustine, Regorafenib - Glioblastoma | Phase 2 / Phase 3 | Recruiting | Global Coalition for Adaptive Research | 2250 | 2019-07-30 | 2026-11-02 |
| Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control BHV-4157 - Spinocerebellar Ataxias | Completed | Biohaven Therapeutics Ltd. | 909 | 2019-03-18 | 2026-10-29 | |
| Randomized Trial of Adult Participants With Generalized Anxiety Disorder Troriluzole, Placebo - Generalized Anxiety Disorder | Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 881 | 2019-02-19 | 2024-05-08 |
| Study of BHV-4157 in Alzheimer's Disease troriluzole, Placebo oral capsule - Alzheimer Disease | Phase 2 | Completed | Biohaven Pharmaceuticals, Inc. | 350 | 2018-07-31 | 2023-12-06 |
| Open Pilot Trial of BHV-4157 BHV-4157 - Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1 | Phase 3 | Active not recruiting | University of California, Los Angeles | 24 | 2017-12-15 | 2024-05-09 |
| Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA) Troriluzole - SCA, Spinocerebellar Ataxias | Available | Biohaven Pharmaceuticals, Inc. | 2026-01-09 |
Spinocerebellar Ataxias (3) · Glioblastoma (2) · Alzheimer Disease (1) · Brain Neoplasms (1) · Generalized Anxiety Disorder (1) · Machado-Joseph Disease (1) · Melanoma (1) · Recurrence (1)
Biohaven Pharmaceuticals, Inc. (3) · Biohaven Therapeutics Ltd. (1) · Dana-Farber Cancer Institute (1) · Global Coalition for Adaptive Research (1) · Ugonma Chukwueke (1) · University of California, Los Angeles (1)
United States (7) · Australia (1) · Canada (1) · France (1) · Germany (1) · Switzerland (1)
Ann W Silk, MD, MS (1) · Tim Cloughesy, MD (1) · Ugonma Chukwueke, MD (1)